Перегляд вихідного коду сторінки Xity of cancer biology: Pitfalls and guarantee. Semin. Cancer Biol. 2012, 22, 250?60. Longo

2013, 31, 1592?605. Lee, J.H.; Kim, D.G.; Bae, T.J.; Rho, K.; Kim, J.T.; Lee, J.J.; Jang, Y.; Kim, B.C.; Park, K.M.; Kim, S.; et al. National overall [https://www.medchemexpress.com/Oprozomib.html get PR-047] health spending projections by way of 2020: Financial recovery and reform drive more rapidly spending growth. Fleck, L.M. Last possibility therapies: Can a just and caring society do well being care rationing when life itself is at stake? Yale J. Overall health Policy Law Ethics 2002, two, 255?98. 31. Daniels, N.; Sabin, J.E. Final chance therapies and managed care: Pluralism, fair procedures, and legitimacy. Hastings Cent. Rep. 1998, 28, 27?1. 32. Calabresi, G.; Bobbitt, P. Tragic Possibilities; W.W. Norton and Organization: New York, NY, USA, 1978. 33. Bock, C.; Lengauer, T. Managing drug resistance in cancer: Lessons from HIV therapy. Nat. Rev. Cancer 2012, 12, 494?01.Xity of cancer biology: Pitfalls and promise. Semin. Cancer Biol. 2012, 22, 250?60. Engl. J. Med. 2012, 366, 956?57. Yap, T.A.; Omlin, A.; de Bono, J.S. Improvement of therapeutic combinations targeting main cancer signaling pathways. J. Clin. Oncol. 2013, 31, 1592?605. Lee, J.H.; Kim, D.G.; Bae, T.J.; Rho, K.; Kim, J.T.; Lee, J.J.; Jang, Y.; Kim, B.C.; Park, K.M.; Kim, S.; et al. CDA: Combinatorial drug discovery applying transcriptional [https://dx.doi.org/10.3389/fpsyg.2016.01448 title= fpsyg.2016.01448] response modules. PLoS A single 2012, 7, e42573. Castano, Z.; Fillmore, C.M.; Kim, C.F.; McAllister, S.S. The bed as well as the bugs: Interactions amongst the tumor microenvironment and cancer stem cells. Semin. Cancer Biol. 2012, 22, 462?70. Prasasya, S.D.; Tian, D.; Kreeger, P.K. Evaluation of cancer signaling networks by systems biology to create therapies. Semin. Cancer Biol. 2011, 21, 200?06. The Cancer Genome Atlas Analysis Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, doi:10.1056/NEJMoa1301689. Steensma, D.P. The beginning of your end from the starting in cancer genomics. N. Engl. J. Med. 2013, doi:10.1056/NEJMe1303816. Gatenby, R.A. A transform of technique within the war on cancer. Nature 2009, 459, 508?09. Keehan, S.P.; Sisko, A.M.; Truffer, C.J.; Poisal, J.A.; Cuckler, G.A.; Madison, A.J.; Lisovitz, J.M.; Smith, S.D. National overall health spending projections by means of 2020: Financial recovery and reform drive quicker spending development. Overall health Aff. 2011, 30, 1594?605.J. Pers. Med. 2013,21. Callahan, D. What kind of Life: The Limits of Health-related Progress; Simon   Schuster: New York, NY, USA, 1990; Chapter 2. 22. American Heart Association Statistics Committee. Heart disease and stroke statistics--2012 update: [https://dx.doi.org/10.4278/ajhp.120120-QUAN-57 title= ajhp.120120-QUAN-57] A report from the American Heart Association. Circulation 2012, 125, e2 220 23. Siegal, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11?0. 24. Wildavsky, A. Performing superior and feeling worse: The political pathology of wellness policy. Daedalus 1977, 106, 105?23. 25. Fojo, T.; Parkinson, D.R. Biologically targeted cancer therapy and marginal benefits: Are we making as well substantially of as well tiny or are we achieving also little by giving as well significantly? Clin. Cancer Res.